US Patent 11285210 Buffer formulations for enhanced antibody stability
Patent 11285210 was granted and assigned to Outlook Therapeutics, Inc. on March, 2022 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11285210 Buffer formulations for enhanced antibody stability
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
